Bactifree

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bactifree

What is Bactifree? A Topical Anti-Infective Agent

Property Description
Active Ingredient Mupirocin (as the Calcium salt)
Form Ointment (Topical preparation)
Pharmacological Class Antibiotic / Topical Anti-infective
General Purpose Resolution of bacterial skin infections
Origin Biosynthetically-derived (from Pseudomonas fluorescens)

What Type of Medicine is Bactifree and How is it Classified?

Bactifree is a prescription-only topical anti-infective agent belonging to the pharmacological class of antibiotics. Its sole active component is Mupirocin Calcium, a monocarboxylic acid derivative with a distinct chemical structure. Mupirocin is classified as an agent used for targeted bacterial skin infections. This specific topical focus allows the medicine to be used effectively in both pediatric and adult patient populations, concentrating its effect at the site of infection.

Bactifree’s Form, Delivery, and Biosynthetic Origin

The medicine is supplied as an ointment, a topical preparation that is applied directly to the affected skin. This ensures the topical route of administration, allowing for localized action. The active Mupirocin compound is biosynthetically-derived, produced through the fermentation process of Pseudomonas fluorescens. Topical application achieves high drug concentrations at the target site, which is crucial for successfully eradicating the bacterial pathogen. This effective topical delivery is clinically recognized for providing a potent response against susceptible bacteria with minimal systemic exposure.

What is the General Purpose of Bactifree?

The general purpose of Bactifree is to resolve bacterial dermatoses by interfering with the survival and proliferation of susceptible bacteria on the skin surface. The mechanism involves Mupirocin acting as a highly specific protein synthesis inhibitor. The compound exerts a dual action, where Mupirocin is capable of exerting both a bacteriostatic effect (halting growth) and a potent bactericidal effect (killing the pathogens). This dual capability is a unique functional feature for topical agents and provides assurance that the microbiological cause of the infection is decisively addressed.

What side effects are possible with Bactifree?

Possible Side Effects and Safety Information

The safety profile for Bactifree (Mupirocin Ointment) is formally documented in government regulatory sources, classifying potential adverse reactions by frequency and the body system affected. These documents emphasize that most reported effects are localized to the area of application.

Documented Adverse Reactions

Adverse reactions are classified based on the standard frequency framework used by regulatory agencies.

Classification Examples of Reactions (by SOC)
Common Burning localized to the area of application.
Uncommon Localized itching, stinging, erythema (redness), dryness, and cutaneous sensitisation reactions.
Very Rare Systemic allergic reactions (e.g., anaphylaxis, generalized rash).

Serious adverse events officially documented include systemic allergic reactions such as anaphylaxis and angioedema. Additionally, as with nearly all antibacterial agents, there is a regulatory note concerning the risk of Clostridium difficile-Associated Diarrhea (CDAD).

Safety Constraints and Special Populations

Safety information specifies limitations related to the use of the medicine. The ointment is not suitable for ophthalmic use (eyes), mucosal surfaces, or for application at the site of central venous cannulation.

Special consideration is required for patients with renal impairment. Due to the polyethylene glycol vehicle used in the ointment, use should be avoided where significant absorption is possible, particularly in individuals with moderate or severe renal impairment. The regulatory safety profile for the pediatric population is generally considered comparable to that of adults.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Bactifree (Mupirocin Ointment) indicates that systemic overdose of the active ingredient, Mupirocin, is not anticipated due to its minimal systemic absorption. The documented risks primarily concern the Polyethylene Glycol excipient base in specific exposure scenarios.


Element Official Regulatory Statement
Exposure-related factors Overdose risk is linked to accidental oral ingestion of a large quantity or use over large areas of damaged skin.
Physiological systems affected The renal system is the system of concern, with a potential for nephrotoxicity due to the Polyethylene Glycol base.
Population-specific notes Patients with pre-existing moderate or severe renal impairment are flagged as an at-risk group for excipient complications.
Emergency action required Seek immediate medical attention or contact the national poison control center if the ointment is accidentally swallowed in a large amount.

Official Overdose Statements

  • No specific antidote is known for Mupirocin overdose; management is required to be symptomatic and supportive.
  • Close monitoring of renal function is necessary following significant exposure, particularly in patients with pre-existing renal impairment.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile by stating that systemic toxicity from the active ingredient is not anticipated due to its poor absorption. The official guidance mandates urgent help-seeking only for specific exposure circumstances, such as accidental oral ingestion, reflecting the risk associated with the ointment's excipient rather than the drug's therapeutic compound. Close monitoring is a required management procedure for at-risk patients exposed to large amounts of the Polyethylene Glycol base.

Therapeutic Uses of Bactifree

What Bactifree Treats: Main Uses and Benefits

Bactifree (Mupirocin Ointment) is a prescription-only topical medication used in the field of dermatology to manage infections caused by susceptible bacteria. It is primarily relevant in contexts marked by localized bacterial skin infections such as Impetigo caused by Staphylococcus aureus and Streptococcus pyogenes. It is applied across domains where additional symptomatic support is needed.


Key Therapeutic Applications

This medication is commonly used across conditions presenting with acute episodes of superficial bacterial infection. Indications include the management of Impetigo, localized Folliculitis, and minor Furuncles (boils). It is also considered relevant for treating secondary bacterial involvement in clinical scenarios involving existing skin trauma like cuts and abrasions, or conditions such as eczema and dermatitis flares.

“Topical treatment supports the management of distinct symptomatic patterns, including the oozing and crusting that characterize localized skin infections.”

Resolution of Symptom Clusters

Bactifree helps address symptom clusters that may become intense or disruptive, including oozing sores, the development of honey-colored crusts, and associated localized redness and discomfort. The medication assists with maintaining functional stability and contributes to easing the overall symptom load during periods of heightened symptoms. This may help patients cope more steadily while supporting the process of healing.


Quick Fact: Relief for Crusting and Oozing

Quick Fact Relief for Crusting and Oozing
Symptom Focus Active lesions, pus, and fluid discharge leading to crusts.
Patient Benefit Supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Regulatory References

  1. DailyMed official label for Mupirocin Ointment

Eligibility and Restrictions for Use

Who Can and Cannot Use Bactifree? Official Regulatory Information

The eligibility for Bactifree (Mupirocin Ointment) is governed by specific regulatory constraints detailing who is approved for use and who must avoid the medicine.

Eligibility Scope and Contraindications

Bactifree is officially established for use in adults and pediatric patients 2 months of age and older. Use is strictly contraindicated for individuals with a known allergy or documented hypersensitivity reaction to mupirocin or any component of the ointment base.

Age and Condition-Based Restrictions

The medicine's safety and effectiveness have not been established in children younger than two months of age. Use is also restricted for populations with compromised renal function. The ointment is not recommended for application over large areas of broken skin in patients with moderate or severe renal impairment, a caution tied to the potential absorption of the polyethylene glycol excipient.

Conditional Use and Site Restrictions

Use during pregnancy is permitted only if clearly needed. For breastfeeding women, if the product is applied to the breast or nipple, the area must be thoroughly washed prior to nursing. Furthermore, the product is not suitable for use near intravenous cannulae, at central venous sites, or for ophthalmic purposes.

What should I know about interactions with other medicines?

The official interaction profile for Bactifree (Mupirocin Ointment) is narrowly defined by its topical application and its formulation's excipient, as systemic drug-drug interactions are minimal. Regulatory sources confirm that the product's effect when administered concurrently with other systemic medications has not been formally studied or reported, leading to an absence of documented pharmacokinetic (e.g., CYP enzyme) or pharmacodynamic interactions. The product's high specificity and localized action contribute to this limited systemic interaction profile.

A mandatory restriction is placed on local co-administration. The ointment must not be mixed or applied at the same time with any other topical preparations, such as lotions, creams, or ointments. This regulatory rule is in place to prevent the dilution of Bactifree, which would lead to a reduction in its antibacterial activity and potential stability issues, thereby compromising its therapeutic effect.

Furthermore, an interaction-related constraint exists for a specific patient population linked to an ingredient in the ointment base. The polyethylene glycol (PEG) excipient in the formulation should not be used in conditions where large quantities of PEG could be absorbed, particularly over large, broken skin areas. This restriction is specifically emphasized for patients who have evidence of moderate or severe renal impairment, due to the way the body processes and clears the excipient. There are no known official interactions documented with food, alcohol, or herbal products.

Mechanism of Action

Molecular Targeting and Protein Synthesis Inhibition

The drug's mechanism of action is highly specific, focused on inhibiting the bacterial enzyme Isoleucyl-tRNA Synthetase (IleRS). By acting as a competitive inhibitor at this single target, Mupirocin prevents the synthesis of essential protein building blocks, thereby crippling the entire bacterial protein synthesis pathway. This molecular intervention is the primary functional step in the mechanism.


Concentration-Dependent Bactericidal Cascade

The immediate cessation of protein synthesis rapidly disrupts the pathogen's ability to grow, leading to a bacteriostatic effect at lower concentrations. However, the high local drug concentration achieved through application quickly escalates this cascade to a pronounced bactericidal effect, causing the irreversible structural and functional collapse of the bacterial cell. The mechanism exploits key structural differences between the bacterial IleRS and the human enzyme, which confines its functional consequences to susceptible microbes.


Mechanism Limitations: Genetic Resistance

The mechanism is significantly constrained by acquired genetic resistance, particularly through the presence of the mupA gene. This gene allows the pathogen to produce a structurally different, alternative IleRS enzyme that is highly resistant to Mupirocin binding. This physiological bypass prevents the drug from inhibiting the resistant pathogen's protein synthesis.

Dosage and Administration Information

Bactifree is a topical 2% Mupirocin Ointment that follows a defined use protocol for treating localized bacterial skin infections. The medication is strictly intended for topical application only to the skin. This instruction specifies that it must not be used intranasally, ophthalmically, or on other mucosal surfaces, nor should it be used near intravenous cannulae or central intravenous sites.

The regimen specifies applying a small amount of the ointment directly to the affected area three times daily. This frequency is established to maintain consistent local drug exposure throughout the 24-hour cycle. The overall course of treatment is designed to last up to 10 days. Should there be no visible clinical response within the first 3 to 5 days of administration, the patient is re-evaluated.

From a procedural standpoint, the treated area may be covered with a sterile gauze dressing following application if deemed appropriate. The administration protocol advises against applying the ointment concurrently with other topical products. For use in specific populations, safety and effectiveness are established for children aged 2 months and older. A constraint related to the ointment's vehicle advises avoiding application to large open wounds or damaged skin in patients with known moderate or severe renal impairment due to the limited renal excretion of the polyethylene glycol base.

Recent Clinical Evidence

Bactifree: Recent Clinical Evidence

The research evidence for Bactifree (Mupirocin Ointment) consists of research from its clinical evaluation for specific bacterial skin infections, as documented in pivotal clinical trials, regulatory submissions, and peer-reviewed scientific literature. The research landscape consists primarily of short-term randomized controlled trials (RCTs), systematic reviews, and trials that monitor responses over defined time intervals.


Evidence for Primary Localized Bacterial Skin Infections

Clinical research has focused on conditions characterized by acute episodes of superficial bacterial infection, most notably Impetigo caused by susceptible strains of Staphylococcus aureus and Streptococcus pyogenes. Researchers conducted pivotal, short-term Randomized Controlled Trials (RCTs) to explore research scenarios comparing Bactifree to an inactive cream (vehicle) or an established active comparator. These studies primarily examined clinical cure (assessing symptom resolution) and bacteriological eradication (eliminating the causative bacteria). Studies reported measurements of symptom resolution and pathogen clearance in the observed populations. The evidence provided was considered adequate to inform the regulatory review for its designated use.


Evidence for Secondary Bacterial Infections

Research examined infections that arise secondary to existing skin trauma, such as infected cuts, abrasions, or underlying dermatoses like eczema. The research exploring this scenario often involved active-controlled trials, where Bactifree was evaluated in research scenarios against other active oral or topical antibiotics. These studies monitored outcomes related to clinical improvement scores and the rate of bacterial clearance from the secondarily infected sites.


Research Gaps, Populations, and Follow-up

Clinical trials included a broad spectrum of pediatric patients, including infants as young as a few months old, and adults. The evidence for use in adults and children is considered to be the best documented part of the research base. However, the typical follow-up duration in these regulatory studies extended only through the end of treatment (usually 7 to 10 days) and a final post-treatment visit shortly thereafter. Consequently, there is limited information for long-term outcomes regarding the durability of the response or the rate of reappearance of infection. Furthermore, the results reflect the specific conditions under which they were conducted, focusing primarily on localized, uncomplicated infections. The research provides limited insight into the course of more extensive infections or those involving deeper tissue.

Key Studies & References Mupirocin Ointment USP Drug Label and Information (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Bactifree (FAQ)


Q: How quickly does Bactifree start working for most people?

Official guidance indicates that a visible response is generally expected within the first few days. Regulatory documents instruct healthcare professionals to re-evaluate a patient's condition if there is no clinical response after 3 to 5 days of treatment.


Q: What are the most common side effects people complain about with Bactifree?

Regulatory documents state that the most frequently reported local adverse reactions in clinical trials are those experienced at the application site. These commonly include a localized feeling of burning, stinging, or pain, as well as localized itching.


Q: Is it normal to feel a bit tired when you first start Bactifree?

Fatigue or tiredness is generally not listed among the common or known systemic adverse reactions documented in the official product information for topical mupirocin ointment. The medication primarily works on the skin surface with minimal body-wide absorption.


Q: Does Bactifree need to be taken with food, or does it matter?

As Bactifree is a topical ointment applied directly to the skin, it is not ingested. Therefore, official product information does not include instructions about food intake.


Q: How long does Bactifree stay in your system after the last dose?

Mupirocin is poorly absorbed through intact skin. If any amount is absorbed systemically, it is rapidly converted to an inactive substance called monic acid. This inactive substance is then cleared from the body, primarily through the kidneys.


Q: Can I take my regular vitamins or supplements while taking Bactifree?

Due to the medicine's topical application and minimal systemic absorption, the risk of drug-drug interactions with oral supplements is not expected. However, regulatory guidance advises against mixing or applying Bactifree concurrently with any other topical product, including herbal or vitamin-based ointments.


Q: Is Bactifree considered safe during pregnancy (high-level, non-advisory)?

Regulatory information indicates that the use of Bactifree during pregnancy is permitted only if clearly needed. In the US classification system, it is considered a Pregnancy Category B drug, meaning animal studies have not shown risk, but human data is limited.


Q: Is Bactifree safe for people with kidney problems (high-level)?

Regulatory information highlights a specific caution for individuals with kidney issues. Bactifree is not recommended for application over large areas of broken skin in patients with moderate or severe renal impairment. This is due to the potential absorption of a component in the ointment base that is processed by the kidneys.


Q: Can Bactifree affect the effectiveness of birth control pills?

Official information states that systemic drug-drug interactions are minimal because Bactifree is poorly absorbed into the bloodstream. Due to this minimal absorption, an effect on oral contraceptives is not expected and has not been documented in regulatory sources.


Q: What should I do if I miss a dose of Bactifree?

If a dose is missed, it can be applied as soon as the person remembers. However, if it is almost time for the next scheduled dose, the person should skip the missed dose and continue the regular schedule. It is important not to apply a double amount to compensate for a missed dose.


Q: Can Bactifree interact with natural or herbal remedies?

No systemic interactions are expected because the absorption of the medicine into the body is minimal. However, Bactifree must not be mixed or applied at the same time with any other topical preparation, which includes certain natural or herbal ointments, as this could reduce its effectiveness.


Q: Is it safe to drink alcohol in moderation while using Bactifree?

There are no known official interactions documented with alcohol, as the medicine is for topical use with minimal systemic absorption. Official product information contains no specific warnings about alcohol consumption.


Q: Why is Bactifree sometimes prescribed when other drugs didn't work?

Bactifree has a specific chemical structure and a distinct mode of action that targets the bacterial enzyme Isoleucyl-tRNA Synthetase. This mechanism generally does not show cross-resistance with many other common antibiotics, offering a unique mode of action.


Q: Can Bactifree be crushed or split if it's a tablet?

Bactifree is supplied solely as a topical ointment and is applied directly to the skin. The medicine is not manufactured as a tablet or capsule.


Q: Is Bactifree a drug that needs to be refrigerated?

No. Official storage guidelines advise that Bactifree should be stored at controlled room temperature (typically below 25 C or 30 C). It is specifically noted in the product information that the ointment should not be frozen.


Q: Are there any known side effects related to mental health or mood with Bactifree?

Adverse reactions related to changes in mental health or mood disorders are generally not reported in the official prescribing information for topical mupirocin. The effects are mostly limited to the application site.


Q: Can you drive or operate machinery while taking Bactifree?

The official product characteristics state that Bactifree has no or negligible influence on the ability to drive or use machines. This is because the medication is applied topically and is not absorbed into the body in significant amounts that would impair function.


Q: How does Bactifree affect your gut flora or good bacteria?

Although it is applied topically, regulatory sources include a warning about the potential risk of Clostridium difficile-Associated Diarrhea (CDAD). This condition occurs when the normal, helpful bacteria in the colon are disrupted, which is a possibility associated with the use of antibacterial agents.


Q: What is the success rate of Bactifree in clinical trials?

In pivotal clinical trials focused on treating impetigo, the clinical cure rate at follow-up was reported to be around 93% in the evaluable patient populations. This rate was reported for the specific infection and patient population studied in the pivotal trials.


Q: What happens when you accidentally take too much Bactifree (informational)?

The toxicity of the active ingredient is considered very low. In the case of accidental oral ingestion, no specific severe adverse effects are generally anticipated. Monitoring of kidney function may be required if a patient with existing renal problems ingested a very large quantity.


Q: Are there any known allergens in Bactifree?

Yes, Bactifree is contraindicated (should not be used) for individuals with a history of allergy or documented hypersensitivity reaction to mupirocin itself. It is also contraindicated for patients allergic to any of the excipients (inactive ingredients) in the ointment base, such as polyethylene glycol.


Q: Can Bactifree cause dizziness or headaches?

Dizziness is not listed in the official adverse reactions. Headaches have been reported as a less common or rare side effect in some post-marketing surveillance reports, though they are not frequently observed in clinical trials.


Q: Are there documented cases where Bactifree has failed to work?

Effectiveness can be limited if the bacteria causing the infection have developed acquired genetic resistance. This means the bacteria can produce a different enzyme (mupA gene) that allows the drug to be bypassed, causing the treatment to fail against that specific strain.


Q: Is Bactifree a prescription-only medication, or can you buy it over the counter?

Bactifree is regulated as a prescription-only medicine. This means that the product is obtained only through a prescription issued by a licensed healthcare provider.


Q: Do people develop a tolerance to Bactifree if they use it often?

Prolonged or repeated use of Bactifree may result in the overgrowth of non-susceptible organisms, including fungi. This overuse can also lead to the development of bacterial resistance, which can diminish the drug's effectiveness for future infections.


Q: Is Bactifree used for preventing certain conditions, or only for treating them?

The official product labeling indicates that Bactifree is approved for the topical treatment of specific bacterial skin infections, such as impetigo.


Q: What is the difference between bacteriostatic and bactericidal effect?

Mupirocin works in two ways. At lower concentrations, it has a bacteriostatic effect, meaning it arrests or stops the growth of the bacteria. At the high concentrations achieved on the skin, it has a strong bactericidal effect, meaning it actively kills the bacterial pathogens.

How should Bactifree be stored and disposed of?

The storage and disposal of Bactifree (Mupirocin Ointment) must align strictly with regulatory requirements to preserve the drug's stability and ensure safety.

Domain Official Storage/Handling Requirements
Temperature & Stability Store at controlled room temperature (e.g., 20 C to 25 C). Do not freeze and do not use after the expiry date on the label.
Protection & Container Keep the medicine out of the sight and reach of children. Store in a tightly closed container, away from excessive heat or moisture, and protected from direct sunlight.

For disposal, the product should be discarded using a drug take-back program if one is available. If not, the ointment should be removed from its container, mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a bag or container, and placed in the household trash. Do not flush Bactifree down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bactifree found in:

A-Z Index: